.



Leonard S. Jacob, M.D.,Ph.D.
Chairman & Chief Executive Officer
Dr. Jacob has served as Chairman of the Board of Directors and Chief Executive Officer of the Company since November 1997. Prior to joining the Company, Dr. Jacob served as the President and Chief Executive Officer of Sangen Pharmaceutical Company and as a consultant to various biotechnology companies from June 1996. From 1989 to 1996, Dr. Jacob, as a co-founder of Genaera Corporation (formerly Magainin Pharmaceuticals, Inc.) (a public biotechnology company), served as Chief Operating Officer. From 1980 to 1988, Dr. Jacob was employed by SmithKline and French Laboratories where he served as Worldwide Vice President and a member of SmithKline Beecham’s Corporate Management Committee. Dr. Jacob serves as a director of the Jacob Internet Fund (a public mutual fund), Macromed Inc. (a private drug delivery company), Carelift International (a non-profit medical relief organization), Recording for the Blind and Dyslexic (a non-profit service organization for the visual and learning disabled) and Saving Face (a non-profit organization for facially disfigured children).

Robert F. Apple
Chief Operating & Financial Officer and Director

Mr. Apple has served as Chief Operating and Financial Officer of the Company since January 2003, Executive Vice President and Chief Financial Officer of the Company from August 2001 to December 2002, Senior Vice President and Chief Financial Officer of the Company from November 1998 to July 2001 and Vice President of Finance and Administration from December 1997 to October 1998. Prior to joining the Company, Mr. Apple was employed by Genaera Corporation, Inc. (formerly Magainin Pharmaceuticals, Inc.) from July 1995 where he held the position of Corporate Controller. From May 1994 until July 1995, Mr. Apple was employed by Liberty Technologies, Inc. (a technology company) as Corporate Controller. From August 1988 until May 1994, Mr. Apple was employed by Arthur Andersen and Company LLP where he held various positions of increasing responsibility.

Martin Rose, M.D., J.D.
Executive Vice President, Research & Development
Dr. Rose, M.D., J.D. has served as Executive Vice President, Research and Development since November 2000 and prior to that, served as Senior Vice President, Clinical Research and Regulatory Affairs since joining the Company in March 1999. Before joining the Company, Dr. Rose was employed by Sparta Pharmaceuticals Inc. from September 1997 where he held the position of Vice President of Clinical Research and Regulatory Affairs. From November 1994 until September 1997, Dr. Rose was employed by BRI International (a pharmaceutical consulting firm) as Senior Consultant. Prior to that, Dr. Rose also held various positions at Alpha I Biomedicals Inc., Genentech Inc. and The United States Food and Drug Administration.

William Harral, III
Director
Mr. Harral has served as a a director of InKine since July 2004. He currently serves as a director of C&D Technologies, Inc., a public manufacturer of reserve power systems and power conservation electronics, since July 1996 and Chairman of the Board since April 1999. He has been President of the Barra Foundation, a private Foundation, since June 2001. Mr. Harral was acting Dean of LeBow College of Business, Drexel University from May 2000 to May 2001 and Executive-in-Residence at Drexel from June 1997 to May 2000. From June 1997 to December 1999, Mr. Harral served as Senior Counselor for The Tierney Group, a strategic communications company. He was President and Chief Executive Officer of Bell Atlantic - Pennsylvania, Inc. (formerly Bell of Pennsylvania) from April 1994 to March 1997. Mr. Harral has served as a Director of The Bryn Mawr Trust Company, a commercial bank, since 1995.

J.R. LeShufy
Director
Mr. LeShufy has served as a director of the Company since December 1995. Mr. LeShufy has been serving as Senior Vice President of Global Hedging Solutions, LLC (a private technology company) since February 2002 and Vice President of Glyconix Corporation (a private biotechnology company) since September 2001. Prior to that, Mr. LeShufy served as President and Chairman of the Board of Trilenium Corporation (a private technology company) for approximately six years ending in May 2001. Mr. LeShufy presently serves as a director of Artwork And Beyond (an organization engaged in art auctions for charities).

Steven B. Ratoff
Director

Mr. Ratoff has served as a director of the Company since February 1998. Mr. Ratoff currently serves as Chairman and interim Chief Executive Officer of Cima Labs, Inc. (a public specialty pharmaceutical company) and has been a director of Cima Labs since January 2002. He served as a director since 1998 and as President and Chief Executive Officer of MacroMed, Inc. (a privately owned drug delivery company) from February 2001 to December 2001. From December 1994 to February 2001, Mr. Ratoff served as Executive Vice President and Chief Financial Officer of Brown-Forman Corporation (a public diversified manufacturer of consumer products). From February 1992 to November 1994, Mr. Ratoff was an investor in a number of small privately held companies. He was Senior Vice President and Chief Financial Officer of the Pharmaceutical Group of Bristol-Myers Squibb (a public pharmaceutical company) from January 1990 to January 1992 and held a number of positions at Bristol-Meyers since joining in 1975.

Norman D. Schellenger
Director
Mr. Schellenger has been a director of the Company since November 2002. Mr. Schellenger has been a consultant to various pharmaceutical companies since 1997, including: Pediamed Pharmaceutical (a private pharmaceutical company), Cebert Pharmaceutical (a private pharmaceutical company), and Proethic Laboratories (a private pharmaceutical company). From September 1994 to December 1996, Mr. Schellenger was Vice President of Sales and Marketing of UCB Pharma (a private pharmaceutical company). Prior to that, Mr. Schellenger was President of Whitby Pharmaceuticals (a private pharmaceutical company) from June 1991 to September 1994. Prior to that Mr. Schellenger held various sales and marketing positions of increasing responsibility at organizations such as Barre National (a private pharmaceutical company), American Home Products, Inc. (formerly Wyeth-Ayerst, a public pharmaceutical company), A.H. Robins (a private pharmaceutical company). Mr. Schellenger is currently managing director of Proethic Laboratories and on the Board of Directors of KV Pharmaceutical Company (a public pharmaceutical company).

Thomas P. Stagnaro
Director
Mr. Stagnaro has served as a director of the Company since November 1997. Mr. Stagnaro has been serving as President and Chief Executive Officer of Agile Therapeutics, Inc. (a private drug development company) since October 2000. From August 1998 to September 2000, Mr. Stagnaro was a consultant to various pharmaceutical and biotechnology companies including the Company. From May 1996 to August 1998, Mr. Stagnaro served as President and Chief Executive Officer of 3-Dimensional Pharmaceuticals (a public biotechnology company). November 1995 to May 1996, Mr. Stagnaro served as Executive Vice President of North American Biologicals Inc. (“NABI”) (a public biotechnology company). Mr. Stagnaro served as President and Chief Executive Officer of Univax Biologics (“Univax”) (a public biotechnology company) from October 1989 to November 1995 when Univax merged into NABI. Mr. Stagnaro currently servs as director of Protalex, Inc. (a public biopharmaceutical Company).